TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05063487

Intervention type: OTHER
Intervention: Return of recent classification
Description: As part of routine HIV case-based surveillance in Rwanda, blood samples are collected for recency testing on the Rapid Test for Recent Infection (RTRI) assay and viral load testing for all newly diagnosed people living with HIV. Results of a recent classification (i.e., having acquired an HIV infection within the last year) will be returned to study participants during a scheduled 1-month visit following initial HIV diagnosis.

Intervention type: OTHER
Intervention: Return of long-term classification
Description: As part of routine HIV case-based surveillance in Rwanda, blood samples are collected for recency testing on the Rapid Test for Recent Infection (RTRI) assay and viral load testing for all newly diagnosed people living with HIV. Results of a long-term classification (i.e., having acquired an HIV infection more than one year ago) will be returned to study participants during the scheduled 1-month visit following initial HIV diagnosis.
Study: NCT05541276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Melatonin for injection 1 mg/mL

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic sodium chloride solution
Description: Sodium chloride 0.9 % for injection
Study: NCT04706507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Ganciclovir
Description: For first 5 days, dosing of intravenous ganciclovir is 10 mg/kg daily, given as 5 mg/kg every 12 hours (adjusted for renal function). After first 5 days (up to 28 days) IV ganciclovir 5 mg/kg QD ( adjusted for renal function). A minimum interval of 6 hours is required between the first and second dose.
Study: NCT05821036

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Activitiy Management
Description: Activity Management training will be applied for 5 weeks, 2 sessions per week, and the 1st and 10th sessions will be pre and post-training evaluation, a total of 10 individual, internet-based sessions.~Week 1:Awareness training and ergonomics training including spine anatomy, correct posture use, ergonomic strategies were planned to increase awareness about FMS. Week 2:Focusing on the challenging activities stated by the individuals, it is aimed to change the behavior by arranging the activity resting cycle in daily life. In addition, the management, adaptation and modification of the activities will be provided within the scope of time management training. Week 3: Joint and energy conservation principles training will be given and it is aimed to create body mechanics and proper posture suitable for activities.Week 4: Relaxation training will be provided as a method of coping with pain.Week 5: Re-evaluation/review of the targets set to reduce pain during activities will be provided.
Study: NCT05537961

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Oriented Recovery Enhancement
Description: Mindfulness instruction incorporated in classroom-based curriculum
Study: NCT04921410

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biofeedback Knee Sleeve
Description: The biofeedback knee sleeve is a device that is artificially-intelligent and utilizes determined cut-off values of knee motion and forces to determine whether a motion is 'good' or 'bad'. A 'bad' knee motion will provide a haptic output to the wearer (biofeedback) so that they can take note of what the previous motion was that caused the device to signal a warning.
Study: NCT04706507

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IV Ganciclovir
Description: For first 5 days, dosing of intravenous ganciclovir is 10 mg/kg daily, given as 5 mg/kg every 12 hours (adjusted for renal function). After first 5 days (up to 28 days) IV ganciclovir 5 mg/kg QD ( adjusted for renal function). A minimum interval of 6 hours is required between the first and second dose.
Study: NCT04842877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valemetostat tosylate
Description: 200mg QD continuously until disease progression, consent withdrawal, unacceptable drug-related toxicity, lost to follow-up, major protocol deviation, pregnancy, termination by sponsor or death, whichever occurs first.
Study: NCT04921410

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Biofeedback
Description: The biofeedback knee sleeve is a device that is artificially-intelligent and utilizes determined cut-off values of knee motion and forces to determine whether a motion is 'good' or 'bad'. This intervention will provide sham biofeedback during training sessions.
Study: NCT06555601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCB3101
Description: Study participants will receive UCB3101 as prespecified in each cohort.
Study: NCT05823129

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele-rehabilitation caregiver empowerment enhanced post- discharge rehabilitation directive
Description: The intervention group will receive an implemented TUG test-based telerehabilitation program. The TUG test-based telerehabilitation involves patients routinely doing two TUG tests by themselves twice daily. Each patient will be provided with a unique link to the TUGstopwatch, a prerecorded video outlining instructions on how to properly conduct a TUG test, and support and guidance for patients and caregivers throughout the study period.
Study: NCT04819074

Intervention type: PROCEDURE
Intervention: Microsurgery
Description: Microsurgery for unruptured intracranial aneurysm
Study: NCT06555601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCB3101
Description: Study participants will receive UCB3101 as prespecified in each cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCB3101
Description: Study participants will receive UCB3101 as prespecified in each cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCB3101
Description: Study participants will receive UCB3101 as prespecified in each cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCB3101
Description: Study participants will receive UCB3101 as prespecified in each cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCB3101
Description: Study participants will receive UCB3101 as prespecified in each cohort.
Study: NCT04969627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Use Metformin for 3 months to treat PCOS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Use Metformin for 3 months to treat PCOS

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Use Metformin for 3 months to treat PCOS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Use Metformin for 3 months to treat PCOS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Use Exenatide for 3 months to treat PCOS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Use Exenatide for 3 months to treat PCOS
Study: NCT04118062

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Questionnaires
Description: Questionnaires

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Questionnaires
Description: Questionnaires

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Questionnaires
Description: Questionnaires
Study: NCT06555601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCB3101
Description: Study participants will receive UCB3101 as prespecified in each cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Study participants will receive placebo as prespecified in each cohort to maintain the blinding.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Study participants will receive placebo as prespecified in each cohort to maintain the blinding.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Study participants will receive placebo as prespecified in each cohort to maintain the blinding.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Study participants will receive placebo as prespecified in each cohort to maintain the blinding.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Study participants will receive placebo as prespecified in each cohort to maintain the blinding.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Study participants will receive placebo as prespecified in each cohort to maintain the blinding.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Study participants will receive placebo as prespecified in each cohort to maintain the blinding.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Study participants will receive placebo as prespecified in each cohort to maintain the blinding.
Study: NCT05641519

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SERVE OC Intervention
Description: SERVE OC intervention for the family which includes 1) Conducting a family intake of risk factors through the LE8 assessment and discussing prevention/risk reduction 2) Facilitate the creation of a family network-tailored action plan 3) Provide guidance to activate/reinforce action plans using the interactive part of the app/web portal. They will meet with their CHW monthly to learn about CVH, work on their goals, and action plans. Meetings with CHWs will take place in their homes, the UCI FQHC in Santa Ana, over zoom, or other locations such as local churches, parks, community centers, or grocery stores (for field trips) They will also receive messages from them throughout the duration of the study using their preferred method of contact (text, email, webportal/app, phone call) for reinforcement and scheduling meetings

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Enhanced Standard Intervention
Description: Enhanced Standard Intervention will be given informational materials from the American Heart Association on cardiovascular health. ESI includes self-management which is standard care
Study: NCT06165250

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BR1018A
Description: One tablet administered alone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR1018A-1
Description: One tablet administered alone
Study: NCT05502601

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical periodontal treatment
Description: SRP will be performed under local anesthesia during a single, 2-hour, full-mouth ultrasonic and hand instrument debridement using curettes.~Oral hygiene instructions (to educate and motivate patients to control the accumulation of plaque and calculus)
Study: NCT04118062

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Questionnaires
Description: Questionnaires

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Semi-structured individual interviews
Description: Semi-structured individual interviews

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Semi-structured individual interviews
Description: Semi-structured individual interviews
Study: NCT04404296

Intervention type: DEVICE
Group type: OTHER
Intervention: 25-gauge, bevel-tip, 20000 cut per minute pars plana vitrectomy
Description: Pars plana vitrectomy using 25-gauge, bevel-tip, 20000 cut per minute vitrectomy probe
Study: NCT04866225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral [14C]PF-06865571
Description: Oral radiolabeled PF-06865571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral PF-06865571
Description: Oral PF-06865571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV [14C]PF-06865571
Description: IV radiolabeled PF-06865571
Study: NCT04344392

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Ultrasonographic study
Description: Thyroid hyoid approximation and hyoid anterior replacement during swallowing. Tongue thickness in rest.
Study: NCT06196710

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Over-the-scope Clips
Description: Over-the-scope Clips is mounted onto a transparent cap, which is attached to the tip of the endoscope. To deploy the claw device, a cogwheel at the scope head is turned pulling a trip string. This in turn retracts the cap releasing the OTSC onto the vessels.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hemo-clipping
Description: Contact thermocoagulation using a 3.3mm probe, hemo-clips, or both. The use of the bipolar device involves firm mechanical compression and coagulation for about 8 seconds.
Study: NCT06341647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB-201
Description: NK Cell Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB-201
Description: NK Cell Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lymphodepleting chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lymphodepleting chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lymphodepleting chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lymphodepleting chemotherapy
Study: NCT05388474

Intervention type: OTHER
Intervention: No ibalizumab or Pre-ibalizumab treatment
Description: Patient registry
Study: NCT04118062

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Semi-structured individual interviews
Description: Semi-structured individual interviews

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Semi-structured individual interviews
Description: Semi-structured individual interviews

Intervention type: OTHER
Group type: OTHER
Intervention: Focus Group
Description: Focus Group

Intervention type: OTHER
Group type: OTHER
Intervention: Focus Group
Description: Focus Group

Intervention type: OTHER
Group type: OTHER
Intervention: DELPHI Consensus Method
Description: DELPHI Consensus Method

Intervention type: OTHER
Group type: OTHER
Intervention: DELPHI Consensus Method
Description: DELPHI Consensus Method
Study: NCT05258513

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Supplementation
Description: 8 weeks of placebo supplementation

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GG sourced from Annatto
Description: 8-weeks of Geranylgeraniol supplementation
Study: NCT06248242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edaravone dexborneol
Description: edaravone 10 mg and dexborneol 2.5 mg twice daily
Study: NCT04985513

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ventilation during cardiopulmonary bypass
Description: Ventilation was performed using an inhaled oxygen fraction of 20% and a tidal volume of 5ml/kg at the time of cardiopulmonary bypass.
Study: NCT04344392

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Ultrasonographic study
Description: Thyroid hyoid approximation and hyoid anterior replacement during swallowing. Tongue thickness in rest.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Videofluoroscopic study temporal parameters
Description: Glossopalatine junction opening and closing time, velopharyngeal junction opening and closing time, laryngeal vestibule opening and closing time, upper esophageal sphincter opening and closing time in seconds.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Videofluoroscopic study distance parameters
Description: Hyoid bone horizontal and vertical replacement, thyroid-hyoid approximation (THA) in millimeters.
Study: NCT03459547

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dental implant
Description: Local anesthesia, flap preparation, dental implant insertion, flap suture, healing abutment insertion. Peri-implant soft tissue samples taken prior to implant placement and 24 hours after.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: dental implant
Description: Local anesthesia, flap preparation, dental implant insertion, flap suture, healing abutment insertion. Peri-implant soft tissue samples taken prior to implant placement and 24 hours after.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: dental implant
Description: Local anesthesia, flap preparation, dental implant insertion, flap suture, healing abutment insertion. Peri-implant soft tissue samples taken prior to implant placement and 24 hours after.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: dental implant
Description: Local anesthesia, flap preparation, dental implant insertion, flap suture, healing abutment insertion. Peri-implant soft tissue samples taken prior to implant placement and 24 hours after.
Study: NCT06165250

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BR1018A-1
Description: One tablet administered alone
Study: NCT04981769

Intervention type: DIAGNOSTIC_TEST
Intervention: Covid-19 test
Description: PCR Covid-19 test
Study: NCT06165250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR1018B
Description: One tablet administered alone
Study: NCT05388474

Intervention type: BIOLOGICAL
Intervention: On ibalizumab treatment
Description: Patient registry
Study: NCT06310161

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bright light
Description: Bright light treatment will consist of using the Re-timer device 3 times per week during dialysis sessions for 4 weeks. The Re-timer is worn like a pair of glasses and contains light emitting diodes mounted on the lower portion of the frame. The Re-timer emits blue-green 500 nm light with an intensity of \~500 lux lm/m2. Participants will be instructed to use the device for 60 minutes at the beginning of each dialysis session.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Dim Light
Description: Dim light treatment will use non-light emitting glasses that look identical to Re-Timer for 4 weeks at each dialysis session following baseline assessments. Participants will use the device for 60 minutes at the beginning of their dialysis session.
Study: NCT05452616

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ART first- Therapeutic use trial
Description: ART initiation on the day of enrolment independent of TB investigations in PLHIV with presumptive TB but no signs of CNS disease. The trial uses treatments and drug-doses as per international and national guidelines. All treatment components will be applied at standard dosage and no new substances or alternative indications will be tested.
Study: NCT06165250

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BR1018B
Description: One tablet administered alone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BR1018B-1
Description: One tablet administered alone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BR1018C
Description: One tablet administered alone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR1018C
Description: One tablet administered alone
Study: NCT05452616

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TB results first- Therapeutic use trial
Description: Deferral of ART initiation until active TB has been refuted or confirmed. PLHIV presenting with symptoms (cough, fever, night sweat, weight loss) are defined as presumptive TB, and should have microbiological TB investigations. Routine TB investigations in Malawi and Lesotho usually consist of two sputum bottles for analysis using nucleic acid amplification tests (Xpert MTB/RIF (Ultra)).The trial uses treatments and drug-doses as per international and national guidelines. All treatment components will be applied at standard dosage and no new substances or alternative indications will be tested.
Study: NCT06165250

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BR1018C-1
Description: One tablet administered alone
Study: NCT05309369

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Preferred Music
Description: Participants will listen to selected music using over-ear headphones delivered as 10-minute segments at the top of each hour over the course of 3 hours
Study: NCT02630121

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxymetazoline Hydrochloride
Description: Proportion of the subjects with 50% reduction in AHI.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Proportion of the subjects with 50% reduction in AHI.
Study: NCT06268886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986446
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986446
Description: Specified dose on specified days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified days
Study: NCT04916418

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TTP block with initial dose of placebo (NaCl0.9%) 20 ml per catheter (total volume 40ml), followed by 20 ml per catheter every 8 hours until 72 hours from the first dose has passed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: TTP block with initial dose of ropivacaine 0.5% (5 mg / ml) 20 ml per catheter (total volume 40ml), followed by doses of ropivacaine 0.2% (2 mg / ml) 20 ml per catheter every 8 hours until 72 hours from the first dose has passed.
Study: NCT05309369

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preferred Music
Description: Participants will listen to selected music using over-ear headphones delivered as 10-minute segments at the top of each hour over the course of 3 hours

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Nature Sounds
Description: Participants will listen to nature sounds using over-ear headphones delivered as 10-minute segments at the top of each hour over the course of 3 hours

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nature Sounds
Description: Participants will listen to nature sounds using over-ear headphones delivered as 10-minute segments at the top of each hour over the course of 3 hours
Study: NCT05604404

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supine
Description: The patient will be positioned supine with head-of-bed at zero degrees.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Semi-Recumbent
Description: The patient will be placed in a semi-recumbent position with head-of-bed at thirty degrees.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Semi-Recumbent with Legs Flexed
Description: The patient will be placed in a semi- recumbent position with head-of-bed at thirty degrees and legs flexed.
Study: NCT05462691

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tuberosity suture
Description: to suture or not suture the tuberosities in reverse shoulder arthroplasty because of a proximal humeral fracture
Study: NCT06022900

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online training group
Description: online health education with video call
Study: NCT05462691

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tuberosity suture
Description: to suture or not suture the tuberosities in reverse shoulder arthroplasty because of a proximal humeral fracture
Study: NCT06022900

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Face-to-face training group
Description: Face-to-face health education with home visit